alternative "first step" agent, to be prescribed (as with diuretic agents) in submaximal doses and later, if necessary, in full doses . With JNC-Ill, nonpharntacologic therapy was introduced, and other concepts such as step-down therapy and evaluation forother cardiovascular risk factors were encouraged . In JNC-111, the angiotensin-converting enzyme (ACE) inhibitors and 'alcium antagonists were included among the initial therapeutic options . This broader spectrum of agents also permitted a more individualized selection of therapy based on certain clinical and demographic characteristics.
Over these 20 years of a national hypertension education program, for health care professions as well as the general public, continued reductions in morbidity and mortality ensued: Stroke deaths decreased by >_60% and deaths from coronary heart disease by almost 50% . Indeed, with the publication last month of the primary prevention document on hypertension (1), for the first time the estimated number of patients with hypertension, defined as blood pressure >89 mm Hg, has been reduced-by approximately 17%-to 50 million Americans .
Accompanying this primary prevention document was the publication of JNC-V, which has once again underscored the dramatic and continued evolution of our concepts about hypertensive disease and antihypertensive therapy (2) . Among changes are : 1 . Description of a new staging of the severity of hypertensive disease that excludes the term mild hypertension .
2. Inclusion of systolic pressure elevations in this severity staging of hypertensive disease.
3. An expanded section on the evaluation of patients with hypertension to include manifestations of target organ involvement ; situations for use of noninvasive, automated ambulatory blood pressure monitoring devices ; further significance of laboratory tests and diagnostic procedures and more recent concepts on community blood pressure control programs.
4. Because of current concerns about health care economics, there is greater discussion of the cost of care and strategies related to the long-term follow-up of patients with hypertension.
5. The concept of nonpllalmacologic approaches to the management of hylertension was modified to that of life-F OHLICH EDITO IAL style changes, now including exercise as an antihypertensive modality .
6. Initial drug therapy options were expanded to include alpha,-and alpha-beta-adreaergic receptor blocking agents .
7. In considering th=s broader option of initial therapies, the document indicates that the "diuretics and beta-blockers are preferred because a reduction in morbidity and mortality has been demonstrated" and that the other initial options that include "the ACE inhibitors, calcium antagonists, alpha ;-and alpha-beta adrenergie receptor blockers have not been tested or shown to reduce morbidity and mortality ." This concept was deemed appropriate in view of recent reports on the efficacy of antihypertensive therapy in several multicenter trials involving elderly patients. However, since submission of this consensus report, other multicentor trials, using compounds from the latter classes of agents, have shown a reduction in morbidity and mortality in normotensive cardiovascular patients .
8 . Because the recent expansion of knowledge concerning treatment of special populations of patients with hypertension also includes patients with special demographic characteristics and coexisting diseases, the section on individualized antihypea tensive therapy has been considerably expanded .
9 . The foregoing special situations encompass other con-JACC Vol . 2 2 , No. 2 August 1993:621-2 siderations including hypertension in women, isolated systolic hypertension in the elderly, hypertension associated with cyclosporine, shock wave renal lithotripsy, cocaine and erythropoietin-induced -hypertension . 10 . harmacologic tables were updated to include new drugs and drug classes, mechanisms of drug action, drugdrug interactions and drugs to be used in hypertensive crises and refractory hypertension .
All in all, there has been a tremendous evolution in the recommendations of the Joint National Committee and this is clear with its fifth consensus report . Should a reprint of this report be of interest, please direct your requests for reprints to the High Blood ressure Education rogram, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 31, oom 4A05, Bethesda, Maryland 20892 . eferences
